YOLFTbeta
Quantum BioPharma Ltd.

Quantum BioPharma Ltd.

QNTM · NASDAQ · Healthcare / Biotechnology

1.61USD-0.17 (-9.55%)

Price History

Full chart

Market Stats

Previous Close1.78
Open1.75
Day Range1.60 – 1.77
52-Week Range2.07 – 19.30
Volume86.34K
Market Cap24.75M
P/E (TTM)0.00
Forward P/E0.00
EPS-4.49
Dividend Yield0.00%
Beta0.45
50-Day Avg3.28
200-Day Avg4.59

About

Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company's lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It also develops FSD-PEA, which is in preparation for Phase 2 trial for the treatment of inflammatory diseases, such as mast cell activation syndrome; Lucid-PSYCH to treat major depressive disorder; and unbuzzd, a dietary supplement for the treatment of alcohol misuse. In addition, the company maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd. was founded in 1998 and is based in Toronto, Canada.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Zeeshan Saeed
  • Employees0
  • Headquarters1 Adelaide Street East, Toronto, ON, Canada, M5C 2V9, USA
  • Websitehttps://www.quantumbiopharma.com

Leadership

  • Mr. Zeeshan SaeedCo-Founder, CEO & Executive Non-Independent Co-Chairman · b. 1970
  • Mr. Anthony John DurkaczCo-Founder & Executive Non-Independent Co-Chairman · b. 1976
  • Mr. Donal Carroll C.M.A., CPAChief Financial Officer · b. 1977
  • Dr. Ashwini Joshi M.S.Director of Pharmaceutical Development
  • Dr. Patrick Onyango Ph.D.Director of Operations at U.S.
  • Mr. Jason David SawyerHead of Finance & Mergers and Acquisitions · b. 1972
  • Ms. Maryann AdessoCorporate Secretary
  • Randell MackPresident of FSD BioSciences
  • Mr. Kevin CassidyVice President of Quality-Lucid

Financials

Income Statement

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--20.63K--000000
Cost of Revenue---182.61K2.04M----490.57K555.33K
Gross Profit--20.63K-182.61K-2.65M-----490.57K-555.33K
Gross Margin--100.00%--------
Operating Expense--2.82M-27.93M----15.65M14.75M
Operating Income---2.80M--30.58M-30.69M-33.74M-27.43M-23.79M-16.14M-15.30M
Operating Margin---13586.02%--------
EBITDA-32.80K-29.63K-2.80M-16.54M-31.98M-24.32M-29.82M-22.12M-15.72M-14.38M-25.79M
EBITDA Margin---13586.02%--------
Net Income-32.80K-29.63K-2.80M-22.64M-39.13M-31.80M-35.29M-23.61M-17.90M-14.20M-26.18M
Net Income Margin---13586.02%--------
R&D-----7.83M6.33M6.91M3.86M6.08M2.76M
Interest Expense----155.32K235.58K69.40K48.82K29947.58K618.64K

Balance Sheet

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets2.16K7.14K10.88M38.75M43.22M41.97M62.96M38.41M17.47M17.12M11.14M
Total Liabilities60.53K61.43K1.01M1.28M6.94M5.66M8.83M7.87M4.57M6.68M6.05M
Total Equity-58.37K-54.30K9.87M37.47M36.28M36.31M54.13M30.54M13.24M11.48M6.91M
Cash-7.14K3.77M15.52M5.97M17.52M35.26M16.98M2.76M6.00M1.90M
Total Debt18.04K---1.59M510.61K555.90K516.42K339.20K824.92K1.87M
Net Debt18.04K-7.14K-3.77M-15.52M-4.38M-17.01M-34.70M-16.46M-2.42M-5.17M-29.09K

Cash Flow

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-63.44-27.24K-119.18K-13.58M-13.71M-19.13M-20.75M-28.33M-10.83M-6.88M-8.38M
Investing Cash Flow---6.09M-7.34M-230.89K6.51M268.96K12.12M-269.58K-1.50M-1.99M
Financing Cash Flow-34.38K9.95M32.95M4.01M24.17M38.21M-2.07M-3.13M11.62M6.21M
Capital Expenditure006.09M2.96M293.13K3.46500.00K363.96K2.21.430
Free Cash Flow-63.44-27.24K-6.21M-16.54M-14.01M-19.13M-21.25M-28.70M-10.83M-6.88M-8.38M
FCF to OCF100.00%100.00%5206.95%121.81%102.14%100.00%102.41%101.28%100.00%100.00%100.00%

Earnings

Report DateJun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Aug 28, 2019Nov 29, 2019Mar 2, 2020May 15, 2020Aug 7, 2020Nov 12, 2020Mar 17, 2021May 20, 2021Aug 12, 2021Nov 15, 2021Mar 30, 2022Apr 1, 2022Aug 12, 2022Nov 11, 2022Mar 31, 2023May 18, 2023Aug 11, 2023Nov 15, 2023Mar 29, 2024May 14, 2024Aug 14, 2024Nov 12, 2024Mar 28, 2025May 12, 2025Aug 6, 2025Nov 6, 2025May 6, 2026Aug 13, 2026Nov 6, 2026
EPS Estimate-------92.30--72.15-46.48-1.06----68.25---0.00---0.14-0.14-3.25-3.90-3.90--0.00-3.70-0.68-0.59-
EPS Actual38.1829.12-150.29-16.28-98.74-108.35-177.45-73.79-0.50-84.50-10.55-24.02-0.35-0.15-10.55-9.60-7.47-12.130.00-16.61-0.14-0.03-9.75-3.25-5.20-4.17-2.70-2.33-3.06-1.77-4.17-0.47-
Surprise-------92.25%-99.30%-81.80%-895.24%---84.54%------78.57%-6864.29%0.00%-33.33%-6.92%---52.16%-513.24%20.34%-
Timing------After-hours--After-hours----After-hours--------After-hours-After-hours-After-hours-After-hoursAfter-hoursAfter-hours-

Key Statistics & Ratios

Market Cap24.75M
Enterprise Value28.16M
Trailing P/E0.00
Forward P/E0.00
Price / Sales91.86
Price / Book3.91
EPS-4.49
Book Value1.05
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-11.78M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-621.46%
Return on Assets-51.84%
Shares Outstanding6.43M
Shares Float7.63M
Beta0.45
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
9.61%
Insiders
8.40%
Retail / Other
81.99%

Top Institutional Holders

  • Group One Trading, LLC
    3480.95%
  • Platform Technology Partners
    41.12K0.00%
  • Jane Street Group LLC
    31.50K0.00%
  • Citadel Advisors Llc
    15.86K0.00%
  • Marex Group Ltd
    13.47K0.00%
  • Virtu Financial LLC
    12.28K0.00%
  • Mariner Wealth Advisors LLC
    10.06K0.00%
  • UBS Group AG
    7.24K0.00%
  • Advisor Group Holdings, Inc.
    6.38K0.00%
  • Steward Partners Investment Advisory, LLC
    4.38K0.00%
  • Global Retirement Partners, LLC.
    3.00K0.00%
  • Atlantic Union Bankshares Corp
    1.00K0.00%
  • JONES FINANCIAL COMPANIES LLLP
    7000.00%
  • Cetera Trust Co NA
    2500.00%
  • Mercer Global Advisors Inc.
    1900.00%
  • Wells Fargo & Co
    1000.00%
  • Federation des caisses Desjardins du Quebec
    930.00%
  • SBI Securities Co Ltd
    750.00%
  • Tower Research Capital LLC
    710.00%

Top Fund Holders

  • AdvisorShares Psychedelics ETF
    263.24K4.11%

Stock Splits

  • Aug 15, 20241:65
  • Oct 16, 20191:201